search
Back to results

Effectiveness of Urinary Alkalinizing Agents on Kidney Stone Risk

Primary Purpose

Kidney Stone

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Baking Soda
LithoLyte
Sponsored by
University of Wisconsin, Madison
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Kidney Stone

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Must be suitable for the study per clinical judgement of study team members
  • Patient in the UW Health University Hospital Urology Clinic or the Metabolic Stone Clinic
  • Had at least one kidney stone event
  • Greater than or equal to 18 years of age
  • 24 hour urine citrate is less than 420 mg and/or urine pH is less than 5.9
  • Urinary alkalinization is deemed by provider as a necessary therapeutic goal for the subject and may be achieved by any of the three therapies under examination
  • Subject is willing to provide consent and to be randomized into a treatment

Exclusion Criteria:

  • Subject is deemed unsuitable for urinary alkalinizing therapy by study staff
  • Subject is already on a urinary alkalinizing agent
  • Subject is on acetazolamide
  • Subject reports sensitivity to sugar alcohols
  • Subject is under 18 years of age
  • Subject has not completed a 24 hour urine collection within 6 months
  • Subject is pregnant or breastfeeding
  • Subject is unable or unwilling to provide consent
  • Subject is unable or unwilling to be randomized
  • Subject reports they are unwilling or unable to use measuring device required in the baking soda arm of the study

Sites / Locations

  • UW-Madison

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Baking Soda

LithoLyte

Arm Description

Subjects randomized to baking soda will be provided instructions for using baking soda to provide 40 mEq alkali, to be accomplished by dissolving ¼ teaspoon baking soda in water or other beverage (any amount) in the morning on an empty stomach and ½ teaspoon baking soda in water or other beverage again at bedtime, also on an empty stomach.

Subjects randomized to LithoLyte® will be provided 40 mEq of alkali in the form of LithoLyte® and advised to take 20 mEq twice daily according to package instructions, once in morning and once at bedtime; no requirements about proximity to meals are necessary.

Outcomes

Primary Outcome Measures

Change in 24 hour urine citrate
Pre-to-post intervention change in 24-hour urine citrate will be measured Reference range of Urine Citrate: 18 years and older: 320-1240 mg/d 1 year and older: greater than or equal to 150 mg/g.
Change in 24 hour urine pH
Pre-to-post intervention change in 24-hour urine pH will be measured Reference range of Urine pH: Age 0 days and up: 5.0-8.0

Secondary Outcome Measures

Post-intervention 24-hour urine calcium
Urine calcium levels will be measured post intervention. Reference range of Urine Calcium: 0-17 years: up to 6.0 mg/kg/24 hours 18 years and up: 100-300 mg/24 hours
24 hour urine calcium
Reference range of urine calcium: 0-12 years: 7-31 mg/d Male 13 years and older: 16-49 mg/d Female 13 years and older: 13-40 mg/d
Post interventional 24 hour urine supersaturation indices for calcium oxalate
Supersaturation means there are too many salts and not enough fluids in the urine. It's the driving force behind stone formation. Post interventional 24 hour urine supersaturation indices for calcium oxalate will be measured. Reference range: 0-12 years: 7-31 mg/d Male 13 years and older: 16-49 mg/d Female 13 years and older: 13-40 mg/d
Post interventional 24 hour urine supersaturation indices for calcium phosphatase
Supersaturation means there are too many salts and not enough fluids in the urine. It's the driving force behind stone formation. Post interventional 24 hour urine supersaturation indices for calcium phosphatase will be measured. Reference range: Age 18 years and up: 0.4-1.3 g/24 hour
Cost of Treatment as measured by USD spent on the interventional drug
Cost of baking soda versus LithoLyte.
Patient acceptability
Wisconsin Stone-QOL: answers range from a scale of 1-5, or yes/no Study Questionnaire: free text responses, or no/yes/I am no longer taking it

Full Information

First Posted
September 17, 2019
Last Updated
November 12, 2021
Sponsor
University of Wisconsin, Madison
search

1. Study Identification

Unique Protocol Identification Number
NCT04095975
Brief Title
Effectiveness of Urinary Alkalinizing Agents on Kidney Stone Risk
Official Title
Effectiveness of Prescription vs. Non-prescription Urinary Alkalinizing Agents on Kidney Stone Risk
Study Type
Interventional

2. Study Status

Record Verification Date
November 2021
Overall Recruitment Status
Completed
Study Start Date
August 28, 2019 (Actual)
Primary Completion Date
June 24, 2021 (Actual)
Study Completion Date
June 24, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Wisconsin, Madison

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No

5. Study Description

Brief Summary
Randomized treatment trial of baking soda or LithoLyte to determine if baking soda and Litholyte are effective in raising 24 hour urine citrate and pH.
Detailed Description
Participants will not be required to attend any study visits outside of normal clinical encounters. Participants enrolled in the study will be randomized to treatment upon enrollment. Blocked randomization will be conducted, utilizing sex (M/F) and recurrent stone former (Y/N) as algorithm variables. Participants randomized to LithoLyte® will be provided 40 mEq of alkali in the form of LithoLyte® and advised to take 20 mEq twice daily according to package instructions, once in morning and once at bedtime; no requirements about proximity to meals are necessary. Participants randomized to baking soda will be provided instructions for using baking soda to provide 40 mEq alkali, to be accomplished by dissolving ¼ teaspoon baking soda in water or other beverage (any amount) in the morning on an empty stomach and ½ teaspoon baking soda in water or other beverage again at bedtime, also on an empty stomach. The 24-hour urine results that are available upon enrollment will be used for pre-intervention values. The 24-hour results from each participant's followup collection will be used for post-intervention values. Thus, no extra encounters are required for participation in the study. Additionally, no extra tests are required for participation in the study as participants would normally complete a post-treatment 24-hour urine collection anyway. Participants will be screened for eligibility, i.e., by pre-clinic review of schedules and 24-hour urine results. Only those meeting inclusion criteria will be invited to participate and enrolled, provided that informed consent is provided by signing the signature page of the consent/authorization form. The treatment/intervention period is up to 90 days (approximately 3 months). However, it should be noted that, as these are clinical interventions that would be prescribed or recommended anyway, it is expected that participants will continue treatment indefinitely and under supervision of urology and/or Metabolic Stone Clinic providers. If the participant has failed the randomized therapy they are assigned to, they will be clinically assigned a different treatment option and continue to be followed up in routine fashion. Participants will also be asked to complete a medication questionnaire and log, as well as the Wisconsin Stone Quality of Life (WISQOL) questionnaire. All study procedures are considered standard of care, except for: randomization into treatment and the medication questionnaire and log. Protocol Amendment Approved 11/16/2020 removed the UrocitK study arm; the investigators faced challenges recruiting participants during the COVID-19 pandemic and the possibility of being randomized into a prescription drug arm was causing many potential participants to choose not to participate.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Kidney Stone

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
31 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Baking Soda
Arm Type
Active Comparator
Arm Description
Subjects randomized to baking soda will be provided instructions for using baking soda to provide 40 mEq alkali, to be accomplished by dissolving ¼ teaspoon baking soda in water or other beverage (any amount) in the morning on an empty stomach and ½ teaspoon baking soda in water or other beverage again at bedtime, also on an empty stomach.
Arm Title
LithoLyte
Arm Type
Active Comparator
Arm Description
Subjects randomized to LithoLyte® will be provided 40 mEq of alkali in the form of LithoLyte® and advised to take 20 mEq twice daily according to package instructions, once in morning and once at bedtime; no requirements about proximity to meals are necessary.
Intervention Type
Dietary Supplement
Intervention Name(s)
Baking Soda
Intervention Description
Standard baking soda that can be bought from stores.
Intervention Type
Dietary Supplement
Intervention Name(s)
LithoLyte
Intervention Description
LithoLyte is considered a medical food and consists of: potassium citrate, magnesium citrate, sodium bicarbonate, and erythritol.
Primary Outcome Measure Information:
Title
Change in 24 hour urine citrate
Description
Pre-to-post intervention change in 24-hour urine citrate will be measured Reference range of Urine Citrate: 18 years and older: 320-1240 mg/d 1 year and older: greater than or equal to 150 mg/g.
Time Frame
Pre and 24 hour post intervention (up to 90 days)
Title
Change in 24 hour urine pH
Description
Pre-to-post intervention change in 24-hour urine pH will be measured Reference range of Urine pH: Age 0 days and up: 5.0-8.0
Time Frame
Pre and 24 hour post intervention (up to 90 days)
Secondary Outcome Measure Information:
Title
Post-intervention 24-hour urine calcium
Description
Urine calcium levels will be measured post intervention. Reference range of Urine Calcium: 0-17 years: up to 6.0 mg/kg/24 hours 18 years and up: 100-300 mg/24 hours
Time Frame
Enrollment and follow up visit (approximately 90 days)
Title
24 hour urine calcium
Description
Reference range of urine calcium: 0-12 years: 7-31 mg/d Male 13 years and older: 16-49 mg/d Female 13 years and older: 13-40 mg/d
Time Frame
Enrollment and follow up visit (approximately 90 days)
Title
Post interventional 24 hour urine supersaturation indices for calcium oxalate
Description
Supersaturation means there are too many salts and not enough fluids in the urine. It's the driving force behind stone formation. Post interventional 24 hour urine supersaturation indices for calcium oxalate will be measured. Reference range: 0-12 years: 7-31 mg/d Male 13 years and older: 16-49 mg/d Female 13 years and older: 13-40 mg/d
Time Frame
Enrollment and follow up visit (approximately 90 days)
Title
Post interventional 24 hour urine supersaturation indices for calcium phosphatase
Description
Supersaturation means there are too many salts and not enough fluids in the urine. It's the driving force behind stone formation. Post interventional 24 hour urine supersaturation indices for calcium phosphatase will be measured. Reference range: Age 18 years and up: 0.4-1.3 g/24 hour
Time Frame
Enrollment and follow up visit (approximately 90 days)
Title
Cost of Treatment as measured by USD spent on the interventional drug
Description
Cost of baking soda versus LithoLyte.
Time Frame
End of study (approximately 90 days)
Title
Patient acceptability
Description
Wisconsin Stone-QOL: answers range from a scale of 1-5, or yes/no Study Questionnaire: free text responses, or no/yes/I am no longer taking it
Time Frame
End of study (approximately 90 days)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Must be suitable for the study per clinical judgement of study team members Patient in the UW Health University Hospital Urology Clinic or the Metabolic Stone Clinic Had at least one kidney stone event Greater than or equal to 18 years of age 24 hour urine citrate is less than 420 mg and/or urine pH is less than 5.9 Urinary alkalinization is deemed by provider as a necessary therapeutic goal for the subject and may be achieved by any of the three therapies under examination Subject is willing to provide consent and to be randomized into a treatment Exclusion Criteria: Subject is deemed unsuitable for urinary alkalinizing therapy by study staff Subject is already on a urinary alkalinizing agent Subject is on acetazolamide Subject reports sensitivity to sugar alcohols Subject is under 18 years of age Subject has not completed a 24 hour urine collection within 6 months Subject is pregnant or breastfeeding Subject is unable or unwilling to provide consent Subject is unable or unwilling to be randomized Subject reports they are unwilling or unable to use measuring device required in the baking soda arm of the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kristina L Penniston, PhD, RDN, FAND
Organizational Affiliation
University of Wisconsin, Madison
Official's Role
Principal Investigator
Facility Information:
Facility Name
UW-Madison
City
Madison
State/Province
Wisconsin
ZIP/Postal Code
53726
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Effectiveness of Urinary Alkalinizing Agents on Kidney Stone Risk

We'll reach out to this number within 24 hrs